Literature DB >> 2522419

Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation.

P L Fidel1, J W Murphy.   

Abstract

Cyclosporin A (CsA), a potent immunosuppressive drug, was used to explore further the induction, expression, and regulation of lymphoid cells involved in the delayed-type hypersensitivity (DTH) response to cryptococcal antigen(s). We found that the induction of the cells responsible for DTH (TDH cells) was not affected by CsA, but their expression was inhibited in CsA-treated mice. The inhibition of expression of the TDH cells could not be attributed to the Cryptococcus neoformans-specific suppressor T (Ts) cells, even though the Ts cells were induced in CsA-treated mice. Instead, the suppressed expression of the TDH cells in CsA-treated mice was a direct effect of CsA or its products. Our studies with CsA also resulted in the first identification of a population of cells that significantly amplify the anticryptococcal DTH response. The amplifier cells were induced in mice that were given a primary immunizing dose of cryptococcal antigen in complete Freund adjuvant, and they amplified the anticryptococcal DTH response in recipient mice when they were transferred at the time of immunization of the recipient. The amplifier cell population was distinct from the TDH cells in that CsA inhibited the production of the amplifying cells but did not affect the induction of TDH cells. Amplification of the DTH response was a cell-mediated event, since cells but not serum from immunized mice mediated the amplified response in recipient mice. Thus, CsA enabled us to characterize anticryptococcal TDH and Ts cells further and to add to the immune cell circuit of the cryptococcal system a distinct population of cells that amplifies the anticryptococcal DTH response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522419      PMCID: PMC313245          DOI: 10.1128/iai.57.4.1158-1164.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Response: calmodulin, cyclophilin, and cyclosporin a.

Authors:  P M Colombani; A D Hess
Journal:  Science       Date:  1986-08-29       Impact factor: 47.728

2.  The effects of cyclosporin A on the induction, expression and regulation of the immune response to herpes simplex virus.

Authors:  D M Altmann; W A Blyth
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

3.  Human cytotoxic T lymphocytes. II. Frequency analysis of cyclosporin A-sensitive alloreactive cytotoxic T-lymphocyte precursors.

Authors:  D Kabelitz; B Zanker; C Zanker; K Heeg; H Wagner
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

4.  Cyclosporin A does not affect the in vitro induction of antigen-specific delayed-type hypersensitivity-mediating T cells.

Authors:  B Shidani; I Motta; P Truffa-Bachi
Journal:  Eur J Immunol       Date:  1987-02       Impact factor: 5.532

5.  Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice.

Authors:  T S Lim; J W Murphy
Journal:  Infect Immun       Date:  1980-10       Impact factor: 3.441

6.  Regulation of cell-mediated immunity in cryptococcosis. III. Characterization of second-order T suppressor cells (Ts2).

Authors:  J W Murphy; R L Mosley
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

7.  Nature of the suppressor cells mediating prolonged graft survival after administration of extracted histocompatibility antigen and cyclosporine.

Authors:  N Yoshimura; B D Kahan
Journal:  Transplantation       Date:  1985-02       Impact factor: 4.939

8.  Host-etiological agent interactions in intranasally and intraperitoneally induced Cryptococcosis in mice.

Authors:  T S Lim; J W Murphy; L K Cauley
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

9.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  8 in total

1.  Characterization of a cell population which amplifies the anticryptococcal delayed-type hypersensitivity response.

Authors:  P L Fidel; J W Murphy
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

2.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans.

Authors:  J W Murphy; F Schafer; A Casadevall; A Adesina
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response.

Authors:  T McGaha; J W Murphy
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

5.  Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response.

Authors:  J W Murphy
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

6.  Regulation of cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response.

Authors:  K L Buchanan; J W Murphy
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

7.  Effects of Cryptococcus neoformans-specific suppressor T cells on the amplified anticryptococcal delayed-type hypersensitivity response.

Authors:  K L Buchanan; P L Fidel; J W Murphy
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

8.  Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells.

Authors:  G B Huffnagle; J L Yates; M F Lipscomb
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.